SG11201808440YA - Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab - Google Patents
Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fabInfo
- Publication number
- SG11201808440YA SG11201808440YA SG11201808440YA SG11201808440YA SG11201808440YA SG 11201808440Y A SG11201808440Y A SG 11201808440YA SG 11201808440Y A SG11201808440Y A SG 11201808440YA SG 11201808440Y A SG11201808440Y A SG 11201808440YA SG 11201808440Y A SG11201808440Y A SG 11201808440YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- fully
- translationally modified
- ocular diseases
- street
- Prior art date
Links
- 208000022873 Ocular disease Diseases 0.000 title abstract 2
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 208000002780 macular degeneration Diseases 0.000 abstract 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 abstract 1
- 206010029113 Neovascularisation Diseases 0.000 abstract 1
- ZJPGOXWRFNKIQL-JYJNAYRXSA-N Phe-Pro-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=CC=C1 ZJPGOXWRFNKIQL-JYJNAYRXSA-N 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 244000191761 Sida cordifolia Species 0.000 abstract 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003511 endothelial effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 210000001525 retina Anatomy 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 229910052709 silver Inorganic materials 0.000 abstract 1
- 239000004332 silver Substances 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662323285P | 2016-04-15 | 2016-04-15 | |
| US201762442802P | 2017-01-05 | 2017-01-05 | |
| US201762450438P | 2017-01-25 | 2017-01-25 | |
| US201762460428P | 2017-02-17 | 2017-02-17 | |
| PCT/US2017/027650 WO2017181021A1 (en) | 2016-04-15 | 2017-04-14 | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808440YA true SG11201808440YA (en) | 2018-10-30 |
Family
ID=60041925
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808440YA SG11201808440YA (en) | 2016-04-15 | 2017-04-14 | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
| SG10202008378UA SG10202008378UA (en) | 2016-04-15 | 2017-04-14 | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202008378UA SG10202008378UA (en) | 2016-04-15 | 2017-04-14 | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20190127455A1 (enExample) |
| EP (1) | EP3442577A4 (enExample) |
| JP (3) | JP2019515027A (enExample) |
| KR (2) | KR20190003556A (enExample) |
| AU (2) | AU2017250797A1 (enExample) |
| CA (1) | CA3019665A1 (enExample) |
| IL (1) | IL262277A (enExample) |
| SG (2) | SG11201808440YA (enExample) |
| WO (1) | WO2017181021A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| WO2017117464A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| MA44873A (fr) | 2016-04-15 | 2019-03-13 | Univ Pennsylvania | Composition pour le traitement de la dégénérescence maculaire liée a l'âge exsudative |
| KR20200060456A (ko) * | 2017-09-27 | 2020-05-29 | 리젠엑스바이오 인크. | 완전-인간 번역후 변형된 항-VEGF Fab를 이용한 안구 질환의 치료 |
| JP2021506861A (ja) | 2017-12-19 | 2021-02-22 | アコーオス インコーポレイテッド | 内耳への治療用抗体のａａｖ媒介送達 |
| US20210093734A1 (en) * | 2018-02-20 | 2021-04-01 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-realted macular degeneration |
| BR112020017872A2 (pt) | 2018-03-02 | 2020-12-22 | Kodiak Sciences Inc. | Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos |
| BR112020025268A2 (pt) * | 2018-06-28 | 2021-03-09 | The University Of North Carolina At Chapel Hill | Cassetes de expressão e genes cln5 otimizados e seu uso |
| JP2022506613A (ja) * | 2018-11-07 | 2022-01-17 | アコーオス インコーポレイテッド | 内耳の有毛細胞及び支持細胞における遺伝子欠陥／発現タンパク質を修正するためのアデノ随伴ウイルスベクターの使用 |
| CN113966236A (zh) | 2019-04-03 | 2022-01-21 | 再生生物股份有限公司 | 眼睛病状的基因疗法 |
| BR112021021156A2 (pt) * | 2019-04-24 | 2022-02-08 | Regenxbio Inc | Terapêuticos anticorpos totalmente humanos pós-tradução modificados |
| CA3148870A1 (en) * | 2019-08-22 | 2021-02-25 | The Regents Of The University Of California | Ube3a for the treatment of angelman syndrome |
| WO2021041373A1 (en) | 2019-08-26 | 2021-03-04 | Regenxbio Inc. | Treatment of diabetic retinopathy with fully-human post-translationally modified anti-vegf fab |
| CN114728049A (zh) | 2019-10-07 | 2022-07-08 | 再生生物股份有限公司 | 腺相关病毒载体药物组合物和方法 |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CN113952474A (zh) * | 2020-07-21 | 2022-01-21 | 英斯培瑞有限公司 | 用于治疗眼部疾病的组合物和方法 |
| JP2023544803A (ja) | 2020-10-07 | 2023-10-25 | レジェンクスバイオ インコーポレーテッド | Ｃｌｎ２疾患の眼症状に対する遺伝子療法 |
| AU2021358964A1 (en) | 2020-10-07 | 2023-05-25 | Regenxbio Inc. | Formulations for suprachoroidal administration such as formulations with aggregate formation |
| WO2022076549A1 (en) | 2020-10-07 | 2022-04-14 | Regenxbio Inc. | Formulations for suprachoroidal administration such as high viscosity formulations |
| US20230414788A1 (en) | 2020-10-07 | 2023-12-28 | Regenxbio Inc. | Formulations for suprachoroidal administration such as gel formulations |
| CN116528892A (zh) * | 2020-10-28 | 2023-08-01 | 再生生物股份有限公司 | 用于眼部适应症的载体化抗TNF-α抗体 |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| CN116917491A (zh) * | 2020-12-18 | 2023-10-20 | Ac免疫有限公司 | 抗体递送 |
| EP4284335A1 (en) | 2021-02-01 | 2023-12-06 | RegenxBio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| US20250026833A1 (en) * | 2021-03-31 | 2025-01-23 | WuXi Biologics Ireland Limited | A bispecific anti-pd-l1/vegf antibody and uses thereof |
| AU2023250660A1 (en) | 2022-04-06 | 2024-10-24 | Regenxbio Inc. | Pharmaceutical composition comprising a recombinant adenoassociated virus vector with an expression cassette encoding a transgene for suprachoroidal administration |
| TW202345913A (zh) | 2022-04-06 | 2023-12-01 | 美商銳進科斯生物股份有限公司 | 用於脈絡膜上投與之調配物諸如凝膠調配物 |
| TW202404651A (zh) | 2022-04-06 | 2024-02-01 | 美商銳進科斯生物股份有限公司 | 用於脈絡膜上投與之調配物諸如形成聚集體之調配物 |
| IL319873A (en) | 2022-09-30 | 2025-05-01 | Regenxbio Inc | Treatment of eye diseases with recombinant viral vectors containing anti-VEGF FAB |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001029242A2 (en) * | 1999-10-21 | 2001-04-26 | Monsanto Company | Post-translational modification of recombinant proteins produced in plants |
| CN1461342A (zh) * | 2000-07-26 | 2003-12-10 | 路德维格癌症研究所 | 糖基化vegf－b和增加可溶性vegf－b量的方法 |
| PE20120622A1 (es) * | 2009-06-17 | 2012-05-26 | Abbott Biotherapeutics Corp | Anticuerpos anti-vegf y sus usos |
| US20130090375A1 (en) * | 2011-10-06 | 2013-04-11 | Cornell University | Virus-mediated delivery of bevacizumab for therapeutic applications |
| TWI775096B (zh) * | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| SG11201609207SA (en) * | 2014-05-13 | 2016-12-29 | Univ Pennsylvania | Compositions comprising aav expressing dual antibody constructs and uses thereof |
-
2017
- 2017-04-14 AU AU2017250797A patent/AU2017250797A1/en not_active Abandoned
- 2017-04-14 SG SG11201808440YA patent/SG11201808440YA/en unknown
- 2017-04-14 US US16/093,363 patent/US20190127455A1/en not_active Abandoned
- 2017-04-14 KR KR1020187032191A patent/KR20190003556A/ko not_active Ceased
- 2017-04-14 KR KR1020237043995A patent/KR20240005973A/ko active Pending
- 2017-04-14 JP JP2019505138A patent/JP2019515027A/ja active Pending
- 2017-04-14 SG SG10202008378UA patent/SG10202008378UA/en unknown
- 2017-04-14 CA CA3019665A patent/CA3019665A1/en active Pending
- 2017-04-14 WO PCT/US2017/027650 patent/WO2017181021A1/en not_active Ceased
- 2017-04-14 EP EP17783242.5A patent/EP3442577A4/en active Pending
-
2018
- 2018-10-10 IL IL262277A patent/IL262277A/en unknown
-
2019
- 2019-03-22 US US16/361,884 patent/US20190211091A1/en not_active Abandoned
-
2022
- 2022-03-25 US US17/704,170 patent/US20230057519A1/en not_active Abandoned
- 2022-07-06 JP JP2022108815A patent/JP2022153418A/ja active Pending
-
2024
- 2024-08-09 AU AU2024205641A patent/AU2024205641A1/en active Pending
- 2024-09-05 JP JP2024152809A patent/JP2025000642A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3019665A1 (en) | 2017-10-19 |
| JP2019515027A (ja) | 2019-06-06 |
| EP3442577A1 (en) | 2019-02-20 |
| AU2017250797A1 (en) | 2018-10-25 |
| KR20240005973A (ko) | 2024-01-12 |
| US20190211091A1 (en) | 2019-07-11 |
| US20230057519A1 (en) | 2023-02-23 |
| KR20190003556A (ko) | 2019-01-09 |
| IL262277A (en) | 2018-11-29 |
| NZ746655A (en) | 2025-05-02 |
| WO2017181021A1 (en) | 2017-10-19 |
| JP2025000642A (ja) | 2025-01-07 |
| US20190127455A1 (en) | 2019-05-02 |
| JP2022153418A (ja) | 2022-10-12 |
| AU2024205641A1 (en) | 2024-09-05 |
| SG10202008378UA (en) | 2020-10-29 |
| EP3442577A4 (en) | 2020-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808440YA (en) | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201810697QA (en) | Chimeric antigen receptor and car-t cells that bind bcma | |
| SG11201810777WA (en) | Purification of multispecific antibodies | |
| SG11201804839WA (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201905699XA (en) | Anti-icos agonist antibodies and uses thereof | |
| SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201808979UA (en) | Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201805828YA (en) | Method of treating c3 glomerulopathy | |
| SG11201806120WA (en) | Ror1 antibody compositions and related methods | |
| SG11201806121PA (en) | Ror2 antibody compositions and related methods | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201901961SA (en) | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x | |
| SG11201906670PA (en) | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases | |
| SG11201806542PA (en) | Anti-mica antibodies | |
| SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201805941WA (en) | Tgfbeta 2 antibodies | |
| SG11201908179UA (en) | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |